Drugs / MT-302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05969041 | Aug 2023 → Aug 2027 expected | epithelial neoplasm | Myeloid Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Myeloid Therapeutics | Results CREATE Medicines Announces Positive First-in-Human Results for MT-302 createmedicines.com ↗
There were no events of grade 3 or higher CRS. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Myeloid Therapeutics | CREATE Medicines Announces Positive First-in-Human Results for MT-302 createmedicines.com ↗ |
| 2025-11-03 | Myeloid Therapeutics | CREATE Medicines to Present Late-Breaking Clinical Data on MT-302 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting createmedicines.com ↗ |
| 2023-09-12 | Myeloid Therapeutics | Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors createmedicines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05969041 ↗ |
| Route | Intravenous | “Participants will receive MT-302 through intravenous infusion.” NCT05969041 ↗ |